{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:14:27Z","timestamp":1793985267028,"version":"4.8.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,7,5]]},"DOI":"10.1038\/s41416-026-03419-9","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:26:27Z","timestamp":1776299187000},"page":"81-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["TLR7 signature of tumour innervation reveals two distinct pathways of triple-negative breast cancer progression"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-287X","authenticated-orcid":false,"given":"Dong-Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-1476","authenticated-orcid":false,"given":"Zhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-6074","authenticated-orcid":false,"given":"Yaacov","family":"Ben-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-988X","authenticated-orcid":false,"given":"Susan J.","family":"Done","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldad","family":"Zacksenhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"3419_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","volume":"5","author":"A Prat","year":"2011","unstructured":"Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5:5\u201323.","journal-title":"Mol Oncol"},{"key":"3419_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346\u201352.","journal-title":"Nature"},{"key":"3419_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.","journal-title":"Nature"},{"key":"3419_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nature17676","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47\u201354.","journal-title":"Nature"},{"key":"3419_CR5","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"3419_CR6","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple-negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"key":"3419_CR7","doi-asserted-by":"publisher","first-page":"10280","DOI":"10.1002\/cam4.5757","volume":"12","author":"M Hattori","year":"2023","unstructured":"Hattori M, Masuda N, Takano T, Tsugawa K, Inoue K, Matsumoto K, et al. Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: results from KEYNOTE-355. Cancer Med. 2023;12:10280\u201393.","journal-title":"Cancer Med"},{"key":"3419_CR8","first-page":"e12","volume":"385","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Rugo HS. Sacituzumab Govitecan in metastatic breast cancer. Reply. N Engl J Med. 2021;385:e12.","journal-title":"N Engl J Med"},{"key":"3419_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288\u2013300.","journal-title":"JAMA"},{"key":"3419_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-007-9632-6","volume":"109","author":"RC Millikan","year":"2008","unstructured":"Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008;109:123\u201339.","journal-title":"Breast Cancer Res Treat"},{"key":"3419_CR11","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1002\/cncr.25276","volume":"116","author":"A Stark","year":"2010","unstructured":"Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer. 2010;116:4926\u201332.","journal-title":"Cancer"},{"key":"3419_CR12","doi-asserted-by":"publisher","first-page":"e055735","DOI":"10.1136\/bmjopen-2021-055735","volume":"12","author":"SM Hercules","year":"2022","unstructured":"Hercules SM, Alnajar M, Chen C, Mladjenovic SM, Shipeolu BA, Perkovic O, et al. Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. BMJ Open. 2022;12:e055735.","journal-title":"BMJ Open"},{"key":"3419_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature"},{"key":"3419_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2007-8-5-r76","volume":"8","author":"JI Herschkowitz","year":"2007","unstructured":"Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8:R76.","journal-title":"Genome Biol"},{"key":"3419_CR15","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121:2750\u201367.","journal-title":"J Clin Investig"},{"key":"3419_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1098-z","volume":"21","author":"DY Wang","year":"2019","unstructured":"Wang DY, Gendoo DMA, Ben-David Y, Woodgett JR, Zacksenhaus E. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. Breast Cancer Res. 2019;21:18.","journal-title":"Breast Cancer Res"},{"key":"3419_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55710-w","volume":"9","author":"DY Wang","year":"2019","unstructured":"Wang DY, Jiang Z, Ben-David Y, Woodgett JR, Zacksenhaus E. Molecular stratification within triple-negative breast cancer subtypes. Sci Rep. 2019;9:19107.","journal-title":"Sci Rep"},{"key":"3419_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39935-y","volume":"14","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Ju Y, Ali A, Chung PED, Skowron P, Wang DY, et al. Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer. Nat Commun. 2023;14:4313.","journal-title":"Nat Commun"},{"key":"3419_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nature23306","volume":"548","author":"DR Robinson","year":"2017","unstructured":"Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548:297\u2013303.","journal-title":"Nature"},{"key":"3419_CR20","doi-asserted-by":"crossref","unstructured":"Zacksenhaus E, Egan SE. Progression to metastasis of solid cancer. Cancers. 2021;13:717.","DOI":"10.3390\/cancers13040717"},{"key":"3419_CR21","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652\u201369.","journal-title":"Cell"},{"key":"3419_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccell.2023.02.012","volume":"41","author":"D Hanahan","year":"2023","unstructured":"Hanahan D, Monje M. Cancer hallmarks intersect with neuroscience in the tumor microenvironment. Cancer Cell. 2023;41:573\u201380.","journal-title":"Cancer Cell"},{"key":"3419_CR23","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","volume":"186","author":"F Winkler","year":"2023","unstructured":"Winkler F, Venkatesh HS, Amit M, Batchelor T, Demir IE, Deneen B, et al. Cancer neuroscience: state of the field, emerging directions. Cell. 2023;186:1689\u2013707.","journal-title":"Cell"},{"key":"3419_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10555-023-10095-1","volume":"42","author":"Q Cui","year":"2023","unstructured":"Cui Q, Jiang D, Zhang Y, Chen C. The tumor-nerve circuit in breast cancer. Cancer Metastasis Rev. 2023;42:543\u201374.","journal-title":"Cancer Metastasis Rev"},{"key":"3419_CR25","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41586-025-08591-1","volume":"640","author":"X Zhi","year":"2025","unstructured":"Zhi X, Wu F, Qian J, Ochiai Y, Lian G, Malagola E, et al. Nociceptive neurons promote gastric tumour progression via a CGRP-RAMP1 axis. Nature. 2025;640:802\u201310.","journal-title":"Nature"},{"key":"3419_CR26","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.ccell.2025.09.003","volume":"43","author":"L Ren","year":"2025","unstructured":"Ren L, Liu C, Cifcibasi K, Ballmann M, Rammes G, Mota Reyes C, et al. Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses. Cancer Cell. 2025;43:2241\u201358.e2248.","journal-title":"Cancer Cell"},{"key":"3419_CR27","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41586-024-08579-3","volume":"639","author":"T Barron","year":"2025","unstructured":"Barron T, Yalcin B, Su M, Byun YG, Gavish A, Shamardani K, et al. GABAergic neuron-to-glioma synapses in diffuse midline gliomas. Nature. 2025;639:1060\u20138.","journal-title":"Nature"},{"key":"3419_CR28","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1016\/j.cell.2025.05.031","volume":"188","author":"R Drexler","year":"2025","unstructured":"Drexler R, Drinnenberg A, Gavish A, Yalcin B, Shamardani K, Rogers AE, et al. Cholinergic neuronal activity promotes diffuse midline glioma growth through muscarinic signaling. Cell. 2025;188:4640\u201357.e4630.","journal-title":"Cell"},{"key":"3419_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/science.1236361","volume":"341","author":"C Magnon","year":"2013","unstructured":"Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341:1236361.","journal-title":"Science"},{"key":"3419_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00485-z","volume":"8","author":"TT Le","year":"2022","unstructured":"Le TT, Payne SL, Buckwald MN, Hayes LA, Parker SR, Burge CB, et al. Sensory nerves enhance triple-negative breast cancer invasion and metastasis via the axon guidance molecule PlexinB3. NPJ Breast Cancer. 2022;8:116.","journal-title":"NPJ Breast Cancer"},{"key":"3419_CR31","doi-asserted-by":"publisher","first-page":"e1001363","DOI":"10.1371\/journal.pbio.1001363","volume":"10","author":"JP Campbell","year":"2012","unstructured":"Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, Penner NL, et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol. 2012;10:e1001363.","journal-title":"PLoS Biol"},{"key":"3419_CR32","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/s41388-021-01691-y","volume":"40","author":"R Wu","year":"2021","unstructured":"Wu R, Li K, Yuan M, Luo KQ. Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells. Oncogene. 2021;40:2165\u201381.","journal-title":"Oncogene"},{"key":"3419_CR33","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","volume":"18","author":"SW Cole","year":"2012","unstructured":"Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18:1201\u20136.","journal-title":"Clin Cancer Res"},{"key":"3419_CR34","doi-asserted-by":"crossref","unstructured":"Covenas R, Munoz M. Involvement of the substance P\/neurokinin-1 receptor system in cancer. Cancers. 2022;14:3539.","DOI":"10.3390\/cancers14143539"},{"key":"3419_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.ads7889","volume":"18","author":"AC Restaino","year":"2025","unstructured":"Restaino AC, Ahmadi M, Eichwald T, Nikpoor AR, Walz A, Balood M, et al. Tumor-infiltrating nociceptor neurons promote immunosuppression. Sci Signal. 2025;18:eads7889.","journal-title":"Sci Signal"},{"key":"3419_CR36","doi-asserted-by":"crossref","unstructured":"Padmanaban V, Keller I, Seltzer ES, Ostendorf BN, Kerner Z, Tavazoie SF. Neuronal substance P drives metastasis through an extracellular RNA-TLR7 axis. Nature. 2024;633:207\u201315.","DOI":"10.1038\/s41586-024-07767-5"},{"key":"3419_CR37","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012118","volume":"12","author":"C Brueffer","year":"2020","unstructured":"Brueffer C, Gladchuk S, Winter C, Vallon-Christersson J, Hegardt C, Hakkinen J, et al. The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome. EMBO Mol Med. 2020;12:e12118.","journal-title":"EMBO Mol Med"},{"key":"3419_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-01987-x","volume":"27","author":"TJ Robinson","year":"2025","unstructured":"Robinson TJ. et al. Association between transcriptomic metrics of exogenous antigen presentation and adaptive immunity with locoregional recurrence in localized estrogen receptor negative breast cancer: retrospective review of multi-institutional datasets. Breast Cancer Res. 2025;27:77.","journal-title":"Breast Cancer Res"},{"key":"3419_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-019-0207-2","volume":"6","author":"SB Lim","year":"2019","unstructured":"Lim SB, Tan SJ, Lim WT, Lim CT. Compendiums of cancer transcriptomes for machine learning applications. Sci Data. 2019;6:194.","journal-title":"Sci Data"},{"key":"3419_CR40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428\u201340 e425.","journal-title":"Cancer Cell"},{"key":"3419_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3035","volume":"13","author":"A Rody","year":"2011","unstructured":"Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, et al. A clinically relevant gene signature in triple-negative and basal-like breast cancer. Breast Cancer Res. 2011;13:R97.","journal-title":"Breast Cancer Res"},{"key":"3419_CR42","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1200\/JCO.22.02511","volume":"41","author":"JS Parker","year":"2023","unstructured":"Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2023;41:4192\u20139.","journal-title":"J Clin Oncol"},{"key":"3419_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-013-2743-3","volume":"142","author":"A Prat","year":"2013","unstructured":"Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, et al. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat. 2013;142:237\u201355.","journal-title":"Breast Cancer Res Treat"},{"key":"3419_CR44","doi-asserted-by":"publisher","first-page":"16387","DOI":"10.1073\/pnas.0901250106","volume":"106","author":"ER Andrechek","year":"2009","unstructured":"Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, et al. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci USA. 2009;106:16387\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3419_CR45","doi-asserted-by":"publisher","first-page":"6994","DOI":"10.1073\/pnas.0912708107","volume":"107","author":"ML Gatza","year":"2010","unstructured":"Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA. 2010;107:6994\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3419_CR46","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1172\/JCI81568","volume":"126","author":"RA Jones","year":"2016","unstructured":"Jones RA, Robinson TJ, Liu JC, Shrestha M, Voisin V, Ju Y, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Investig. 2016;126:3739\u201357.","journal-title":"J Clin Investig"},{"key":"3419_CR47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.celrep.2018.03.039","volume":"23","author":"JC Liu","year":"2018","unstructured":"Liu JC, Granieri L, Shrestha M, Wang DY, Vorobieva I, Rubie EA, et al. Identification of CDC25 as a common therapeutic target for triple-negative breast cancer. Cell Rep. 2018;23:112\u20136.","journal-title":"Cell Rep"},{"key":"3419_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cancergen.2020.08.006","volume":"248-249","author":"SM O\u2019Cathail","year":"2020","unstructured":"O\u2019Cathail SM, Wu CH, Lewis A, Holmes C, Hawkins MA, Maughan T. NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. Cancer Genet. 2020;248-249:1\u201310.","journal-title":"Cancer Genet"},{"key":"3419_CR49","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1172\/JCI27236","volume":"116","author":"P Kaposi-Novak","year":"2006","unstructured":"Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Investig. 2006;116:1582\u201395.","journal-title":"J Clin Investig"},{"key":"3419_CR50","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3419_CR51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267\u201373.","journal-title":"Nat Genet"},{"key":"3419_CR52","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773\u201382.","journal-title":"Nat Biotechnol"},{"key":"3419_CR53","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","volume":"40","author":"DM Wolf","year":"2022","unstructured":"Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022;40:609\u201323.e606.","journal-title":"Cancer Cell"},{"key":"3419_CR54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:497\u2013509.","journal-title":"Lancet Oncol"},{"key":"3419_CR55","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jama.2011.593","volume":"305","author":"C Hatzis","year":"2011","unstructured":"Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305:1873\u201381.","journal-title":"JAMA"},{"key":"3419_CR56","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1073\/pnas.1201105109","volume":"109","author":"JC Liu","year":"2012","unstructured":"Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, et al. Seventeen-gene signature from enriched Her2\/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERalpha- breast cancer. Proc Natl Acad Sci USA. 2012;109:5832\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3419_CR57","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106825","volume":"41","author":"Z Jiang","year":"2022","unstructured":"Jiang Z, Li H, Schroer SA, Voisin V, Ju Y, Pacal M, et al. Hypophosphorylated pRb knock-in mice exhibit hallmarks of aging and vitamin C-preventable diabetes. EMBO J. 2022;41:e106825.","journal-title":"EMBO J"},{"key":"3419_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09176-8","author":"G Hoover","year":"2025","unstructured":"Hoover G, Gilbert S, Curley O, Obellianne C, Lin MT, Hixson W, et al. Nerve-to-cancer transfer of mitochondria during cancer metastasis. Nature. 2025;644:252\u201362.","journal-title":"Nature"},{"key":"3419_CR59","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796\u2013804.","journal-title":"J Clin Oncol"},{"key":"3419_CR60","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35:1049\u201360.","journal-title":"J Clin Oncol"},{"key":"3419_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65048-9","volume":"16","author":"KY Fjaestad","year":"2025","unstructured":"Fjaestad KY, Johansen AZ, Linder H, Baker KJ, Schattefor M, Czajkowski NK, et al. beta-adrenergic signaling blockade attenuates metastasis through activation of cytotoxic CD4 T cells. Nat Commun. 2025;16:10063.","journal-title":"Nat Commun"},{"key":"3419_CR62","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.4049\/jimmunol.163.5.2410","volume":"163","author":"R Suzuki","year":"1999","unstructured":"Suzuki R, Furuno T, McKay DM, Wolvers D, Teshima R, Nakanishi M, et al. Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J Immunol. 1999;163:2410\u20135.","journal-title":"J Immunol"},{"key":"3419_CR63","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1073\/pnas.91.9.3739","volume":"91","author":"A Leon","year":"1994","unstructured":"Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, Aloe L, et al. Mast cells synthesize, store, and release nerve growth factor. Proc Natl Acad Sci USA. 1994;91:3739\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3419_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-030-49270-0_9","volume":"1273","author":"A Aponte-Lopez","year":"2020","unstructured":"Aponte-Lopez A, Munoz-Cruz S. Mast cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1273:159\u201373.","journal-title":"Adv Exp Med Biol"},{"key":"3419_CR65","doi-asserted-by":"crossref","unstructured":"Sulsenti R, Jachetti E. Frenemies in the microenvironment: harnessing mast cells for cancer immunotherapy. Pharmaceutics 2023;15:10063.","DOI":"10.3390\/pharmaceutics15061692"},{"key":"3419_CR66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-025-09370-8","volume":"646","author":"EN Baruch","year":"2025","unstructured":"Baruch EN, Gleber-Netto FO, Nagarajan P, Rao X, Akhter S, Eichwald T, et al. Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy. Nature. 2025;646:462\u201373.","journal-title":"Nature"},{"key":"3419_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-10028-8","author":"HK Wei","year":"2026","unstructured":"Wei HK, Yu CD, Hu B, Zeng X, Ichise H, Li L, et al. Tumour-brain crosstalk restrains cancer immunity via a sensory-sympathetic axis. Nature. 2026;650:1007\u201316","journal-title":"Nature"},{"key":"3419_CR68","doi-asserted-by":"crossref","unstructured":"Zhang SW, Wang H, Xiao Y, Liu LT, Shen M, Wang Z et al. Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. Cell. 2026;189:1039\u201355.","DOI":"10.1016\/j.cell.2026.01.001"},{"key":"3419_CR69","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1172\/JCI41490","volume":"120","author":"Z Jiang","year":"2010","unstructured":"Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, et al. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like\/EMT tumor subtypes depending on p53 status. J Clin Investig. 2010;120:3296\u2013309.","journal-title":"J Clin Investig"},{"key":"3419_CR70","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.trecan.2017.09.002","volume":"3","author":"E Zacksenhaus","year":"2017","unstructured":"Zacksenhaus E, Shrestha M, Liu JC, Vorobieva I, Chung PED, Ju Y, et al. Mitochondrial OXPHOS induced by RB1 deficiency in breast cancer: implications for anabolic metabolism, stemness, and metastasis. Trends Cancer. 2017;3:768\u201379.","journal-title":"Trends Cancer"},{"key":"3419_CR71","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/ncb3039","volume":"16","author":"VS LeBleu","year":"2014","unstructured":"LeBleu VS, O\u2019Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16:992\u20131003. 1001\u201315.","journal-title":"Nat Cell Biol"},{"key":"3419_CR72","unstructured":"Hoang-Minh LB, Siebzehnrubl FA, Yang C, Suzuki-Hatano S, Dajac K, Loche T et al. Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma. Cell. 2026;189:1039\u201355."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03419-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03419-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03419-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:02:31Z","timestamp":1781546551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03419-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,5]]}},"alternative-id":["3419"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03419-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing Interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}